<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224341</url>
  </required_header>
  <id_info>
    <org_study_id>ARREST-AF</org_study_id>
    <nct_id>NCT00224341</nct_id>
  </id_info>
  <brief_title>Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitatron France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitatron France</source>
  <brief_summary>
    <textblock>
      The objective of this trial is to show the therapeutic efficacy of the preventive pacing
      therapies of the Selection 9000 and Vitatron T70 DR pacemakers, dedicated to handle atrial
      fibrillation (AF). Two new algorithms (post-AF response and ventricular rate stabilization
      [VRS]) will be assessed in a combined pathway, compared to a control group. The efficacy of
      the overall available therapies to prevent AF and its symptoms will then be assessed also.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to anti-arrhythmic pharmacological drugs failure to suppress atrial fibrillation (AF),
      interest towards preventive pacing treatments is increasing. The importance of this option in
      the panoply of the preventive tools is fully justified, only by considering the
      insufficiency, the complexity, or the poor reproducibility of the other non-pharmaceutical
      approaches.

      Preventive pacing therapies rely on their potential effect on different onset modalities
      emphasized by previous studies, and more generally by stabilizing atrial tissue when
      potential triggers are appearing.

      On top of that, cardiac stimulator can deliver these therapies when identifying these
      triggers but also can offer incomparable diagnostic tools, in terms of sensitivity,
      specificity and continuity in the monitoring.

      Four preventive pacing therapies have already been evaluated, the objective of this study is
      to show the clinical benefit brought by the new features of the Selection 9000 / Vitatron T70
      DR.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2003</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Show clinical benefit of post-AF response and VRS algorithms, when combined versus compared with a control group: In a conventional dual chamber (DDD) configuration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>In a configuration including all the preventive pacing therapies of the device</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary endpoint is the atrial fibrillation burden.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of post-AF response and VRS, when combined versus compared with a control group, in a conventional DDD configuration and another configuration which includes all PPT, on: Number (Nb) of hospitalizations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nb of cardioversions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restarts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily incidence of AF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sinus rhythm duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess clinical benefit of the overall AF therapies, as compared with the first four algorithms of the previous device (one continuous overdrive +3 triggered overdrive), on the same outcomes as above and AF burden</measure>
  </secondary_outcome>
  <enrollment>360</enrollment>
  <condition>Sick Sinus Syndrome</condition>
  <condition>Brady-Tachy Syndrome</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker Vitatron Selection 9000</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker Vitatron T70</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with documented atrial fibrillation: at least one episode of paroxysmal AF
             documented 6 months prior to inclusion, lasting more than one minute

          -  Patient with a brady-tachy syndrome or a sick sinus syndrome, with a permanent pacing
             indication

          -  Atrial lead with a tip-to-ring interval equal to or less than 12 mm

          -  Patient who agrees with and has signed the informed consent

        Exclusion Criteria:

          -  Permanent AF

          -  AF related to a reversible cause

          -  One electrical cardioversion 6 months prior to inclusion

          -  Unstable angina

          -  Myocardial infarction (MI) less than 3 months

          -  Planned cardiac surgery or performed in the last 3 months

          -  Congestive heart failure, New York Heart Association (NYHA) class IV

          -  Life expectancy less than 18 months

          -  Patient participating in other studies

          -  Patient not able to follow the FU calendar

          -  Less than 18 years of age

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Attuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNOM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christèle Pelade, Engineer</last_name>
    <phone>01 53 98 83 00</phone>
    <email>christele.pelade@vitatron.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bérangère Leroy, Engineer</last_name>
    <phone>01 53 98 83 00</phone>
    <email>berangere.leroy@vitatron.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHG</name>
      <address>
        <city>Abbeville</city>
        <zip>80100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Ernst Poulard, MD</last_name>
      <phone>+33 322255200</phone>
    </contact>
    <investigator>
      <last_name>Jean-Ernst Poulard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Privé</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Gedin, MD</last_name>
      <phone>+33 146743700</phone>
    </contact>
    <investigator>
      <last_name>Didier Gedin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyrus Moini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Auxerre</city>
        <zip>89011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Xavier Soto, MD</last_name>
      <phone>+33 386484658</phone>
    </contact>
    <investigator>
      <last_name>François-Xavier Soto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Mourot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul Faugier, MD</last_name>
      <phone>+33 432753141</phone>
    </contact>
    <investigator>
      <last_name>Jean-Paul Faugier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Bordeaux Cauderan</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Gencel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Gencel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Scanu, MD</last_name>
      <phone>+33 231063106</phone>
    </contact>
    <investigator>
      <last_name>Patrice Scanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Chavernac, MD</last_name>
      <phone>+33 563716328</phone>
    </contact>
    <investigator>
      <last_name>Pascal Chavernac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Plotton, MD</last_name>
      <phone>+33 141466241</phone>
    </contact>
    <investigator>
      <last_name>Christian Plotton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CH René Pleven</name>
      <address>
        <city>Dinan</city>
        <zip>22101</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Bazin, MD</last_name>
      <phone>+33 296857250</phone>
    </contact>
    <investigator>
      <last_name>Patrick Bazin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Dole</city>
        <zip>39108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugues Zimmermann, MD</last_name>
      <phone>+33 384798065</phone>
    </contact>
    <investigator>
      <last_name>Hugues Zimmermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Charles Aisenfarb, MD</last_name>
      <phone>+33 328285623</phone>
    </contact>
    <investigator>
      <last_name>Jean-Charles Aisenfarb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Evreux</city>
        <zip>27000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bouchaib Deriouich, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bouchaib Deriouich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Defaye, MD</last_name>
      <phone>+33 476765507</phone>
    </contact>
    <investigator>
      <last_name>Pascal Defaye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMC Parly II</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Attuel, MD</last_name>
      <phone>+33 139637000</phone>
    </contact>
    <investigator>
      <last_name>Patrick Attuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Le Havre</city>
        <zip>76083</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Cheradame, MD</last_name>
      <phone>+33 232733155</phone>
    </contact>
    <investigator>
      <last_name>Isabelle Cheradame, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre Favier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe D'Ivernois, MD</last_name>
      <phone>+33 555056310</phone>
    </contact>
    <investigator>
      <last_name>Christophe D'Ivernois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Philibert</name>
      <address>
        <city>Lomme</city>
        <zip>59160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Graux, MD</last_name>
      <phone>+33 320225058</phone>
    </contact>
    <investigator>
      <last_name>Pierre Graux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de la Casamance</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Faure, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacques Faure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Bouchard</name>
      <address>
        <city>Marseille</city>
        <zip>13006</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Guenoun, MD</last_name>
      <phone>+33 491159062</phone>
    </contact>
    <investigator>
      <last_name>Maxime Guenoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Roux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Deharo, Pr</last_name>
      <phone>+33 491386575</phone>
    </contact>
    <investigator>
      <last_name>Jean-Claude Deharo, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Martigues</city>
        <zip>136995</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Ebagosti, MD</last_name>
      <phone>+33 442432540</phone>
    </contact>
    <investigator>
      <last_name>André Ebagosti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Boursier, MD</last_name>
      <phone>+33 387553231</phone>
    </contact>
    <investigator>
      <last_name>Michel Boursier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Davy, Pr</last_name>
      <phone>+33 467336164</phone>
    </contact>
    <investigator>
      <last_name>Jean-Marc Davy, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc Pasquié, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franck Raczka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Levy, MD</last_name>
      <phone>+33 389647120</phone>
    </contact>
    <investigator>
      <last_name>Jacques Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Ambroise Paré</name>
      <address>
        <city>Neuilly sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Thomas, MD</last_name>
      <phone>+33 146418965</phone>
    </contact>
    <investigator>
      <last_name>Olivier Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cardiologique du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Clementy, Pr</last_name>
      <phone>+33 557656471</phone>
    </contact>
    <investigator>
      <last_name>Jacques Clementy, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain Reuter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Privé Claude Galien</name>
      <address>
        <city>Quincy-sous-Sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Bleinc, MD</last_name>
      <phone>+33 169399132</phone>
    </contact>
    <investigator>
      <last_name>Dominique Bleinc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint Laurent</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel Baisset, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Michel Baisset, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Mabo, Pr</last_name>
      <phone>+33 299282527</phone>
    </contact>
    <investigator>
      <last_name>Philippe Mabo, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Anselme, MD</last_name>
      <phone>+33 232888111</phone>
    </contact>
    <investigator>
      <last_name>Frédéric Anselme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Savoure, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Da Costa, MD</last_name>
      <phone>+33 477828340</phone>
    </contact>
    <investigator>
      <last_name>Antoine Da Costa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Arnalt Tzanck</name>
      <address>
        <city>Saint Laurent du Var</city>
        <zip>06721</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Mariottini, MD</last_name>
      <phone>++33 4 92 27 37 27</phone>
    </contact>
    <investigator>
      <last_name>Claude Mariottini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Durand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMCO</name>
      <address>
        <city>Schiltigheim</city>
        <zip>67303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Philippot, MD</last_name>
      <phone>+33 3 88628318</phone>
    </contact>
    <investigator>
      <last_name>François Philippot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Thionville</city>
        <zip>57100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Thisse, MD</last_name>
      <phone>+33 382558300</phone>
    </contact>
    <investigator>
      <last_name>Jean-Yves Thisse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Houplon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Canavy, MD</last_name>
      <phone>+33 494616069</phone>
    </contact>
    <investigator>
      <last_name>Isabelle Canavy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alex Baralla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Julienne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benaissa Agraou, MD</last_name>
      <phone>+33 327143041</phone>
    </contact>
    <investigator>
      <last_name>Benaissa Agraou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Fauchier L, Briand F, Soto FX, Quennelle F, Lévy J, Darmon JP, Lellouche D, Lavergne T, Poret P, Pelade C, Babuty D. Management of atrial tachyarrhythmias: benefits of pacemaker diagnostics. Pacing Clin Electrophysiol. 2003 Jan;26(1 Pt 2):233-8.</citation>
    <PMID>12687819</PMID>
  </reference>
  <reference>
    <citation>Camm AJ on behalf of the AFTherapy Study Group. The Atrial Fibrillation Therapy Study. Présentation orale au cours du Congrès de l’ESC à Stockholm, Septembre 2001.</citation>
  </reference>
  <reference>
    <citation>Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG; American College of Cardiology; American Heart Association; European Society of Cardiology; North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001 Oct;22(20):1852-923.</citation>
    <PMID>11601835</PMID>
  </reference>
  <reference>
    <citation>Tse HF, Lau CP, Ayers GM. Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. Heart. 1999 Sep;82(3):319-24.</citation>
    <PMID>10455082</PMID>
  </reference>
  <reference>
    <citation>Falk RH. Management of atrial fibrillation--radical reform or modest modification? N Engl J Med. 2002 Dec 5;347(23):1883-4.</citation>
    <PMID>12466514</PMID>
  </reference>
  <reference>
    <citation>Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1834-40.</citation>
    <PMID>12466507</PMID>
  </reference>
  <reference>
    <citation>Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1825-33.</citation>
    <PMID>12466506</PMID>
  </reference>
  <reference>
    <citation>Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000 Nov 25;356(9244):1789-94.</citation>
    <PMID>11117910</PMID>
  </reference>
  <reference>
    <citation>Hohnloser SH, Kuck KH. Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological Intervention in Atrial Fibrillation Trial (PIAF). Eur Heart J. 2001 May;22(10):801-2.</citation>
    <PMID>11350085</PMID>
  </reference>
  <reference>
    <citation>Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66.</citation>
    <PMID>9725923</PMID>
  </reference>
  <reference>
    <citation>Defaye P, Dournaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol. 1998 Jan;21(1 Pt 2):250-5.</citation>
    <PMID>9474682</PMID>
  </reference>
  <reference>
    <citation>Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997 Oct 25;350(9086):1210-6.</citation>
    <PMID>9652562</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000 May 11;342(19):1385-91.</citation>
    <PMID>10805823</PMID>
  </reference>
  <reference>
    <citation>Gillis AM, Connolly SJ, Lacombe P, Philippon F, Dubuc M, Kerr CR, Yee R, Rose MS, Newman D, Kavanagh KM, Gardner MJ, Kus T, Wyse DG. Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation. The atrial pacing peri-ablation for paroxysmal atrial fibrillation (PA (3)) study investigators. Circulation. 2000 Aug 15;102(7):736-41.</citation>
    <PMID>10942740</PMID>
  </reference>
  <reference>
    <citation>Edvardson N. Efficacy of preventive pacing therapies in Paroxysmal Atrial Fibrillation - IV International meeting - Atrial Fibrillation 2001 : 161-164.</citation>
  </reference>
  <reference>
    <citation>Hoffmann E, Janko S, Steinbeck G and al. Onset scenarios of paroxysmal atrial fibrillation using new diagnostic pacemaker functions. Pacing Clin Electrophysiol. 2000 ; 23(4) : 656 (abstract).</citation>
  </reference>
  <reference>
    <citation>Hoffmann E, Janko S, Steinbeck G and al. Analysis of Onset Mechanisms of Paroxysmal Atrial Fibrillation through a Pacemaker with Continuous Monitoring Capabilities. Pacing Clin Electrophysiol. 2000 ; 23(4) : 656 (poster).</citation>
  </reference>
  <reference>
    <citation>Capucci A, Gropppi F, Ruiter J on behalf of the AFTherapy Study Group. Re-initiation of atrial Fibrillation Investigated Through pacemaker Focussed Diagnostics. Europace 2000 – Supplement 1.</citation>
  </reference>
  <reference>
    <citation>Tse HF, Lau CP, Ayers GM. Atrial pacing for suppression of early reinitiation of atrial fibrillation after successful internal cardioversion. Eur Heart J. 2000 Jul;21(14):1167-76.</citation>
    <PMID>10924300</PMID>
  </reference>
  <reference>
    <citation>Lee JK, Yee R, Braney M, Stoop G, Begemann M, Dunne C, Klein GJ, Krahn AD, Van Hemel NM. Acute testing of the rate-smoothed pacing algorithm for ventricular rate stabilization. Pacing Clin Electrophysiol. 1999 Apr;22(4 Pt 1):554-61.</citation>
    <PMID>10234708</PMID>
  </reference>
  <reference>
    <citation>Lau CP, Jiang ZY, Tang MO. Efficacy of ventricular rate stabilization by right ventricular pacing during atrial fibrillation. Pacing Clin Electrophysiol. 1998 Mar;21(3):542-8.</citation>
    <PMID>9558685</PMID>
  </reference>
  <reference>
    <citation>Daoud EG, Weiss R, Bahu M, Knight BP, Bogun F, Goyal R, Harvey M, Strickberger SA, Man KC, Morady F. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol. 1996 Dec 15;78(12):1433-6.</citation>
    <PMID>8970422</PMID>
  </reference>
  <reference>
    <citation>Yee R, Meijer A and Winkler WB and al. Effect of Chronic Ventricular Rate Stabilization on Rate Irregularity in Patients with Permanent Atrial Fibrillation. Progress in Clinical Pacing – Rome 2002 : 52 (abstract)</citation>
  </reference>
  <reference>
    <citation>Pfaiffer L, Canby P, Navone A and al. Impact of Atrial Rhythm Diagnostics on Clinical Management. Europace Supplements 2002 ; 3 : A 152 (abstract).</citation>
  </reference>
  <reference>
    <citation>Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol. 2002 Nov 6;40(9):1703-19.</citation>
    <PMID>12427427</PMID>
  </reference>
  <reference>
    <citation>Jenkins LS, Bubien RS. Quality of life in patients with atrial fibrillation. Cardiol Clin. 1996 Nov;14(4):597-606. Review.</citation>
    <PMID>8950060</PMID>
  </reference>
  <reference>
    <citation>Carlioz R, Perrier E, Thomas O and al. Accuracy of atrial Tachyarrhythmia Monitoring in the Selection Device : Correlation with an External Holter Recording. Europace Suppl 2001 ; 2 : B199.</citation>
  </reference>
  <reference>
    <citation>Jenkins LS. Quality of life in Patients with Atrial Fibrillation. Circulation 1995 ; 92 (I) : 490 (abstract).</citation>
  </reference>
  <reference>
    <citation>Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996 Oct 1;94(7):1585-91.</citation>
    <PMID>8840848</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>October 17, 2006</last_update_submitted>
  <last_update_submitted_qc>October 17, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2006</last_update_posted>
  <keyword>Pacemaker</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Prevention pacing</keyword>
  <keyword>Algorithms</keyword>
  <keyword>Sick sinus syndrome + Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Sick Sinus Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

